An Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral in Cardiac Transplant Recipients With Established Allograft Vasculopathy.

Trial Profile

An Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral in Cardiac Transplant Recipients With Established Allograft Vasculopathy.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jul 2010

At a glance

  • Drugs Ciclosporin; Everolimus
  • Indications Heart transplant rejection
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 09 Jul 2010 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
    • 24 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top